DK0640131T3 - Gensplejsere antistoffer - Google Patents

Gensplejsere antistoffer

Info

Publication number
DK0640131T3
DK0640131T3 DK93905306T DK93905306T DK0640131T3 DK 0640131 T3 DK0640131 T3 DK 0640131T3 DK 93905306 T DK93905306 T DK 93905306T DK 93905306 T DK93905306 T DK 93905306T DK 0640131 T3 DK0640131 T3 DK 0640131T3
Authority
DK
Denmark
Prior art keywords
pct
antibodies
date sep
sec
melanoma
Prior art date
Application number
DK93905306T
Other languages
Danish (da)
English (en)
Inventor
Norman Hardman
Gerd Pluschke
Brendan Murray
Original Assignee
Novartis Ag
Novartis Erfind Verwalt Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Erfind Verwalt Gmbh filed Critical Novartis Ag
Application granted granted Critical
Publication of DK0640131T3 publication Critical patent/DK0640131T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F02—COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
    • F02B—INTERNAL-COMBUSTION PISTON ENGINES; COMBUSTION ENGINES IN GENERAL
    • F02B75/00—Other engines
    • F02B75/02—Engines characterised by their cycles, e.g. six-stroke
    • F02B2075/022—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle
    • F02B2075/027—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle four
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
DK93905306T 1992-03-17 1993-03-05 Gensplejsere antistoffer DK0640131T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP92810188 1992-03-17
PCT/EP1993/000505 WO1993019180A1 (fr) 1992-03-17 1993-03-05 Anticorps produits par genie genetique

Publications (1)

Publication Number Publication Date
DK0640131T3 true DK0640131T3 (da) 1999-11-01

Family

ID=8211884

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93905306T DK0640131T3 (da) 1992-03-17 1993-03-05 Gensplejsere antistoffer

Country Status (12)

Country Link
US (1) US5866124A (fr)
EP (1) EP0640131B1 (fr)
JP (1) JPH07504802A (fr)
AT (1) ATE179210T1 (fr)
AU (1) AU673347B2 (fr)
CA (1) CA2130173A1 (fr)
DE (1) DE69324579T2 (fr)
DK (1) DK0640131T3 (fr)
ES (1) ES2131107T3 (fr)
GR (1) GR3030702T3 (fr)
MX (1) MX9301500A (fr)
WO (1) WO1993019180A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU672580B2 (en) * 1991-04-18 1996-10-10 Mount Sinai School Of Medicine Of The City University Of New York, The Chimeric immunoglobulin molecules
EP0674907A3 (fr) * 1994-03-21 1996-03-13 Ciba Geigy Ag Conjugués d'un anticorps et d'une protéine porteuse, utiles dans l'immunothérapie active.
DE19911329A1 (de) * 1998-03-27 2000-09-21 Benes Ivan Friedrich Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US7468254B2 (en) * 2003-01-21 2008-12-23 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
MY148646A (en) 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
RU2007139283A (ru) * 2005-03-25 2009-04-27 Гликарт Биотехнологи Аг (Ch) АНТИГЕНСВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ, НАПРАВЛЕННЫЕ К MCSP И ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ АФФИННОСТЬЮ СВЯЗЫВАНИЯ Fc-РЕЦЕПТОРА И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
RU2006112025A (ru) * 2005-12-16 2007-10-27 Хелт Рисерч Инк. (Us) Пептиды для стимуляции иммунного ответа против меланомы
WO2010045495A2 (fr) 2008-10-16 2010-04-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Anticorps entièrement humains dirigés contre un antigène associé au mélanome de masse moléculaire élevée et leurs utilisations
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
WO2012174001A1 (fr) 2011-06-13 2012-12-20 Abgenomics Cooperatief U.A. Anticorps anti-psgl-1 et leurs utilisations
ES2654160T3 (es) 2011-10-04 2018-02-12 Igem Therapeutics Limited Anticuerpos de IgE anti-HMW-MAA
MX2017003247A (es) 2014-09-15 2017-11-30 Amgen Inc Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
JP2021519790A (ja) 2018-04-02 2021-08-12 アムジェン インコーポレイテッド エレヌマブ組成物及びその使用
CN115349490B (zh) * 2022-07-14 2024-01-12 成都中医药大学 一种卵巢储备功能低下动物模型的建立方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0291636A1 (fr) * 1983-11-07 1988-11-23 The Wistar Institute Réponse immunitaire aux virus induits par des anticorps anti-idiotype
US4918164A (en) * 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
EP0380607B1 (fr) * 1988-05-17 1994-12-14 FERRONE, Soldano Anticorps anti-idiotype contre un antigene anti-humain associe a un melanome de poids moleculaire eleve
CA2065414C (fr) * 1989-09-15 2007-05-15 Tse-Wen Chang Traitement des maladies autoimmunes
ATE132906T1 (de) * 1989-11-14 1996-01-15 New York Medical College Neuartige antiidiotypische monoklonale antikörper

Also Published As

Publication number Publication date
EP0640131A1 (fr) 1995-03-01
MX9301500A (es) 1993-12-01
GR3030702T3 (en) 1999-11-30
EP0640131B1 (fr) 1999-04-21
ATE179210T1 (de) 1999-05-15
AU3631393A (en) 1993-10-21
WO1993019180A1 (fr) 1993-09-30
AU673347B2 (en) 1996-11-07
CA2130173A1 (fr) 1993-09-30
DE69324579D1 (de) 1999-05-27
DE69324579T2 (de) 1999-09-23
US5866124A (en) 1999-02-02
JPH07504802A (ja) 1995-06-01
ES2131107T3 (es) 1999-07-16

Similar Documents

Publication Publication Date Title
DK0640131T3 (da) Gensplejsere antistoffer
DE69932084D1 (de) Antikörperfragmente zur lokalen Behandlung von Augenerkrankungen
DE59508864D1 (de) MONOKLONALER ANTIKÖRPER GEGEN CD44v6
EP0671920A4 (fr) Anticorps anti-idiotypique et utilisation diagnostique et therapeutique pour les affections dues au vih.
DE69738984D1 (de) Mutierte nicht aktivierende igg2 domäne und diese sequenz enthaltende anti-cd3 antikörper
NO2015027I1 (no) Mepolizumab
ATE165395T1 (de) Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen
PT741716E (pt) Analogos de delta 12,13-iso-taxol sua utilizacao anti-neoplasica e composicoes farmaceuticas que os contem
DE69942742D1 (de) Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
DK0845998T3 (da) Lægemidler til immunbehandling indeholdende antistoffer, der specifikt genkender MHCII-antigenet hos en patient, der skal behandles
ATE258057T1 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
DK0600396T3 (da) Vacciner mod tarmprotozoer
DE69721485T2 (de) Durch hla-b44 moleküle präsentierte tumor-abstossungsantigene und ihre verwendungen
DK0649433T3 (da) Antigeniske regioner fra komplekser af tumorfrigivne partikler (TLP) og antistoffer mod sådanne.
DK1039931T3 (da) Multivalente rekombinante antistoffer til at behandle HRV infektioner
DE59006159D1 (de) Verwendung von macrolactonen als antiallergica.
GB9715177D0 (en) Medicament
AU3283693A (en) Specific antibodies against activated platelets, the preparation thereof and the use thereof in diagnosis and therapy